No, Asymptomatic Campylobacter jejuni Carriers Should Not Be Treated
Asymptomatic contacts of people with Campylobacter jejuni infection should not receive antimicrobial therapy, but should follow appropriate infection prevention and control measures 1.
Rationale for No Treatment
The 2017 IDSA guidelines explicitly state that asymptomatic contacts of people with acute or persistent watery diarrhea should not be offered empiric or preventive therapy 1. This recommendation applies directly to asymptomatic Campylobacter jejuni carriers for several key reasons:
Evidence Against Treatment in Asymptomatic Carriers
- No demonstrated benefit: Antimicrobial therapy in Campylobacter infections shows benefit only when symptoms are present, with treatment reducing illness duration by approximately 1 day on average 1
- Self-limited disease: Campylobacter infections are typically self-limiting, and most patients do not require antibiotics 2
- No evidence of harm from carrier state: There is no evidence that the carrier state itself causes complications or that avoiding treatment prolongs carriage 1
- Person-to-person spread is uncommon: Drug-resistant Campylobacter transmission between people is not believed to be a common scenario 1
When Treatment IS Indicated (For Context)
Treatment should be reserved for:
- Symptomatic patients with particularly prolonged or severe disease 1
- Immunocompromised hosts with symptomatic gastroenteritis, even if otherwise uncomplicated 1
- Severely ill patients where fatal infections, though rare, are more likely 1, 3
Infection Control Instead of Treatment
The appropriate management for asymptomatic carriers focuses on:
- Proper hand hygiene
- Food safety practices
- Avoiding food preparation for others during the carrier period
- Standard enteric precautions
Important Caveat on Resistance
Fluoroquinolone resistance in Campylobacter is increasing globally, with some regions showing universal resistance 4. This further supports avoiding unnecessary antibiotic use in asymptomatic carriers, as treatment would contribute to resistance without providing clinical benefit.